我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
21
2 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1947
已完成
10
47.6%
尚未招募
2
9.5%
招募中
7
33.3%
Unknown
暂无批准数据
- Hyundai Bioscience's oral antiviral CP-COV03 (Xafty) demonstrated efficacy in treating COVID-19 symptoms in a randomized, double-blind, placebo-controlled trial with 300 patients. - The niclosamide-based drug showed faster recovery times and reduced hospitalization risk compared to placebo, with no serious adverse events reported. - CP-COV03 is positioned as a safer and more effective alternative to existing COVID-19 treatments like Paxlovid, with potential for broader antiviral applications. - The company plans to advance to later-stage trials and seek regulatory approval, with potential market availability next year if successful.
